Neurocrine Biosciences (NBIX) EPS (Basic): 2010-2021
Historic EPS (Basic) for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $0.24.
- Neurocrine Biosciences' EPS (Basic) rose 138.71% to $0.24 in Q3 2021 from the same period last year, while for Sep 2021 it was $4.75, marking a year-over-year increase of 370.30%. This contributed to the annual value of $4.38 for FY2020, which is 995.00% up from last year.
- Per Neurocrine Biosciences' latest filing, its EPS (Basic) stood at $0.24 for Q3 2021, which was down 46.67% from $0.45 recorded in Q2 2021.
- Neurocrine Biosciences' EPS (Basic)'s 5-year high stood at $3.72 during Q4 2020, with a 5-year trough of -$1.12 in Q1 2019.
- Over the past 3 years, Neurocrine Biosciences' median EPS (Basic) value was $0.40 (recorded in 2020), while the average stood at $0.53.
- As far as peak fluctuations go, Neurocrine Biosciences' EPS (Basic) plummeted by 309.09% in 2017, and later skyrocketed by 905.41% in 2020.
- Quarterly analysis of 5 years shows Neurocrine Biosciences' EPS (Basic) stood at $0.08 in 2017, then skyrocketed by 150.00% to $0.20 in 2018, then spiked by 85.00% to $0.37 in 2019, then skyrocketed by 905.41% to $3.72 in 2020, then surged by 138.71% to $0.24 in 2021.
- Its EPS (Basic) was $0.24 in Q3 2021, compared to $0.45 in Q2 2021 and $0.34 in Q1 2021.